Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.69 |
| ▸ | CCNA2 | P20248 | 19/20 | 0.69 |
| ▸ | CCNA1 | P78396 | 19/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.55 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.55 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29659569 | 0.84 | CDK2 (0.79) | CDK2CCNA2CCNA1CDK5CCNB2 | |
| SCHEMBL29659491 | 0.81 | CCNA2 (0.70) | CDK2CCNA2CCNA1 | |
| SCHEMBL5868111 | 0.81 | CDK2 (0.69) | CDK2CCNA2CCNA1CDK5CCNB2 | |
| SCHEMBL27594396 | 0.80 | CDK2 (0.67) | CDK2CCNA2CCNA1CDK5CCNB2 | |
| SCHEMBL6194008 | 0.79 | CDK2 (0.75) | CDK2CCNA2CCNA1CDK5CCNB2 | |
| SCHEMBL5867847 | 0.78 | CDK2 (0.74) | CDK2CCNA2CCNA1CDK5CCNB2 | |
| SCHEMBL5867756 | 0.78 | CCNA2 (0.55) | CDK2CCNA2CCNA1 | |
| SCHEMBL27583845 | 0.78 | CDK2 (0.65) | CDK2CCNA2CCNA1CDK5CCNB2 | |
| SCHEMBL5867559 | 0.76 | CDK2 (0.63) | CDK2CCNA2CCNA1CDK5CCNB2 | |
| SCHEMBL5867732 | 0.76 | CCNA2 (0.62) | CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | claimed |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | AURIGENE ONCOLOGY LTD (IN) | 2024-08-22 | — | — | US | claimed |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-18 | — | — | US | claimed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | claimed |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-31 | — | — | US | claimed |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | AURIGENE ONCOLOGY LTD (IN) | 2024-08-22 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | CDK2 20/4885CCNA2 30/4885CCNA1 37/4885 |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | CDK7, CDK17, CDK6 | CDK2 17/4885CCNA2 46/4885CCNA1 30/4885 |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | CDK7, CDK17, HDAC7 | CDK2 25/4885CCNA2 100/4885CCNA1 75/4885 |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | CDK2 20/4885CCNA2 30/4885CCNA1 37/4885 |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | CDK2 20/4885CCNA2 30/4885CCNA1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.